The reiteration of a Buy rating and maintenance of a $97 price target by a reputable analyst like Ami Fadia from Needham is likely to instill confidence among investors and could positively influence Blueprint Medicines' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.